Cart
sales@molnova.com
Alflutinib
CAS No. 1869057-83-9
Alflutinib( AST2818 | AST-2818 | ASK120067 )
Catalog No. M12888 CAS No. 1869057-83-9
Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 155 | In Stock |
|
| 5MG | 123 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 376 | In Stock |
|
| 50MG | 554 | In Stock |
|
| 100MG | 731 | In Stock |
|
| 200MG | 1042 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAlflutinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionAlflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
-
DescriptionAlflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.Lung Cancer Phase 1 Clinical.
-
In VitroFirmonertinib is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation.
-
In Vivo——
-
SynonymsAST2818 | AST-2818 | ASK120067
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number1869057-83-9
-
Formula Weight568.605
-
Molecular FormulaC28H31F3N8O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C
-
Chemical NameN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. PCT Int. Appl. (2017), WO 2017152707 A1 20170914.
molnova catalog
related products
-
AG 99
AG-99 is an inhibitor of EGFR kinase (IC50: 10 μM in the human epidermoid carcinoma cell line A431).
-
Poziotinib hydrochlo...
Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.?It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.?
-
EGFR-IN-1 hydrochlor...
EGFR-IN-1 hydrochloride is an irreversible and specific inhibitor of L858R/T790M mutant EGFR, with 100-fold selectivity over wild-type EGFR.
